Novel Agent First to Slow Disability in nrSPMS ...Middle East

Medscape - News
The Bruton's tyrosine kinase inhibitor tolebrutinib is reportedly the first agent to show benefit in patients with nonrelapsing secondary progressive MS. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( Novel Agent First to Slow Disability in nrSPMS )

Apple Storegoogle play

Also on site :



Latest News